You are here

  • Home
  • Online First
  • Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis

Article info

Article menu

other Versions

Original research
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis

Authors

  • Brigida Anna Maiorano Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, ItalyTranslational Medicine and Surgery Department, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Rome, Italy PubMed articlesGoogle scholar articles
  • Mauro Francesco Pio Maiorano Department of Biomedical Sciences and Human Oncology, Obstetrics and Gynecology Unit, University of Bari "Aldo Moro", Bari, Italy PubMed articlesGoogle scholar articles
  • Domenica Lorusso Department of Women and Child Health, Division of Gynecologic Oncology, Foundation Policlinic "A. Gemelli" IRCCS, Rome, ItalyScientific Directorate, Foundation Policlinic "A. Gemelli" IRCCS, Rome, Italy PubMed articlesGoogle scholar articles
  • Massimo Di Maio Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy PubMed articlesGoogle scholar articles
  • Evaristo Maiello Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Brigida Anna Maiorano, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo 71013, Italy; b.maiorano{at}operapadrepio.it
View Full Text

Citation

Maiorano BA, Maiorano MFP, Lorusso D, et al
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
International Journal of Gynecologic Cancer Published Online First: 13 October 2022. doi: 10.1136/ijgc-2022-003614

Publication history

  • Received April 17, 2022
  • Accepted September 15, 2022
  • First published October 13, 2022.

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.